Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00914
|
|||||
| Drug Name |
Glycyrrhizin
|
|||||
| Synonyms |
Uralsaponin A; glycyrrhizin; Glycyrrhizic acid; AC1L2TF0; Glycyrrhizin (JAN); Glycyrrhizinate; ZINC96319491; AKOS037514680; AKOS016036159; 3-Hydroxy-11 oxoolean-12-en-30-oic acid-3-O-glucuronopyranosyl-(1-2)glucuronopyranoside; D00157; C02284; beta-D-Glucopyranosiduronic acid, (3beta,20beta)-20-carboxy-11-oxo-30-norolean-12-en-3-yl 2-O-beta-D-glucopyranuronosyl-; (3beta,20beta)-20-Carboxy-11-oxo-30-norolean-12-en-3-yl 2-O-beta-D-glucuronosyl-beta-D-glucosiduronic acid
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Hepatitis C virus infection [ICD11: 1E50.2, 1E51.1] | Approved | [1] | |||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C42H62O16
|
|||||
| Canonical SMILES |
CC1(C2CCC3(C(C2(CCC1OC4C(C(C(C(O4)C(=O)O)O)O)OC5C(C(C(C(O5)C(=O)O)O)O)O)C)C(=O)C=C6C3(CCC7(C6CC(CC7)(C)C(=O)O)C)C)C)C
|
|||||
| InChI |
InChI=1S/C42H62O16/c1-37(2)21-8-11-42(7)31(20(43)16-18-19-17-39(4,36(53)54)13-12-38(19,3)14-15-41(18,42)6)40(21,5)10-9-22(37)55-35-30(26(47)25(46)29(57-35)33(51)52)58-34-27(48)23(44)24(45)28(56-34)32(49)50/h16,19,21-31,34-35,44-48H,8-15,17H2,1-7H3,(H,49,50)(H,51,52)(H,53,54)/t19-,21-,22-,23-,24-,25-,26-,27+,28-,29-,30+,31+,34-,35+,38+,39-,40-,41+,42+/m0/s1
|
|||||
| InChIKey |
LPLVUJXQOOQHMX-MOGLOQIBSA-N
|
|||||
| CAS Number |
CAS 103000-77-7
|
|||||
| Pharmaceutical Properties | Molecular Weight | 822.9 | Topological Polar Surface Area | 267 | ||
| Heavy Atom Count | 58 | Rotatable Bond Count | 7 | |||
| Hydrogen Bond Donor Count | 8 | Hydrogen Bond Acceptor Count | 16 | |||
| XLogP |
3.7
|
|||||
| PubChem CID | ||||||
| ChEBI ID |
CHEBI:561823
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | MRP2 | Transporter Info | Multidrug resistance-associated protein 2 | Substrate | [2] | |
| MRP3 | Transporter Info | Multidrug resistance-associated protein 3 | Substrate | [3] | ||
| References | ||||||
| 1 | National Center for Advancing Translational Science-Inxight: drug (6FO62043WK) | |||||
| 2 | Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007. | |||||
| 3 | The combination of glycyrrhizin and lamivudine can reverse the cisplatin resistance in hepatocellular carcinoma cells through inhibition of multidrug resistance-associated proteins. Int J Oncol. 2007 Dec;31(6):1465-72. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.